Medtronic PLC (MDT), a leading medical device company, saw its stock plunge 5.18% in pre-market trading on Tuesday, following the release of its fiscal third-quarter 2025 earnings results.
The company reported revenue of $8.292 billion for the quarter ended January 24, 2025, slightly missing analyst estimates of $8.324 billion. The GAAP diluted earnings per share (EPS) came in at $1.01, lower than the expected $1.07. Although Medtronic reported non-GAAP diluted EPS of $1.39, beating estimates of $1.36, the overall results fell short of market expectations.
According to the earnings report, Medtronic faced challenges in its Medical Surgical Portfolio, which saw a 1.9% revenue decline attributed to pressures in the stapling segment and changes in distributor buying patterns. However, the company's Cardiovascular, Neuroscience, and Diabetes portfolios showed growth, with the Diabetes segment reporting an impressive 8.4% revenue increase driven by the adoption of the MiniMed™ 780G system.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。